The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study

Background: Nintedanib is an oral multitarget tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Recent evidence demonstrated that nintedanib reduced functional disease progression also in subjects with non-IPF progressive fibrosing interstitia...

Descripción completa

Detalles Bibliográficos
Autores principales: Cameli, Paolo, Alonzi, Valerio, d’Alessandro, Miriana, Bergantini, Laura, Pordon, Elena, Guerrieri, Marco, Refini, Rosa Metella, Sestini, Piersante, Bargagli, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405731/
https://www.ncbi.nlm.nih.gov/pubmed/36009520
http://dx.doi.org/10.3390/biomedicines10081973

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405731/
https://www.ncbi.nlm.nih.gov/pubmed/36009520
http://dx.doi.org/10.3390/biomedicines10081973

Ejemplares similares